

**PLEASE ATTACH THE FOLLOWING SO WE CAN MOST EFFICIENTLY PROCESS THE PATIENT'S ORDER**

- ☐ Patient Demographics ☐ Insurance card ☐ Progress Notes supporting DX ☐ Hepatitis B Results  
☐ Quantitative serum immunoglobulin screening

**PATIENT**

Full Name: \_\_\_\_\_ DOB: \_\_\_\_\_  
Mobile Phone: \_\_\_\_\_ Weight: ☐ lbs ☐ kg  
Allergies: \_\_\_\_\_ ☐ NKDA  
Patient status: ☐ New to therapy ☐ Continuing therapy Last Treatment Date: \_\_\_\_\_ Next Treatment Date: \_\_\_\_\_

**DIAGNOSIS ICD-10 code (must be specified)**

- ☐ Relapsing-remitting multiple sclerosis, ICD 10: G35.A  
☐ Primary progressive multiple sclerosis, unspecified, ICD 10: G35.B0  
☐ Active primary progressive multiple sclerosis, ICD 10: G35.B1  
☐ Non-active primary progressive multiple sclerosis, ICD 10: G35.B2  
☐ Secondary progressive multiple sclerosis, unspecified, ICD 10: G35.C0  
☐ Active secondary progressive multiple sclerosis, ICD 10: G35.C1  
☐ Non-active secondary progressive multiple sclerosis, ICD 10: G35.C2  
☐ Multiple sclerosis, unspecified, ICD 10: G35.D

\*\*Disclaimer: After 10/1/2025 you must specify which type of MS per CMS guidelines.

**PROVIDER**

Provider Name: \_\_\_\_\_ Provider NPI: \_\_\_\_\_  
Practice Name: \_\_\_\_\_ Referral Coordinator Name: \_\_\_\_\_  
Practice Address: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_

**PRE-MEDICATION**

- ☐ Acetaminophen (Tylenol) PO ☐ 500 mg ☐ 650 mg ☐ 1000 mg  
☐ Diphenhydramine (Benadryl) ☐ PO ☐ IV ☐ 25 mg ☐ 50 mg  
☐ Methylprednisolone (Solu-Medrol) IV ☐ 40 mg ☐ 125 mg  
☐ Cetrizine (Zyrtec) 10 mg PO  
☐ Other: \_\_\_\_\_

**THERAPY ADMINISTRATION**

| Medication                                                         | Dose                            | Frequency                                                                                                           |
|--------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------|
| <input checked="" type="checkbox"/> Briumvi (Ublituximab-xiiy), IV | <input type="checkbox"/> 150 mg | <input type="checkbox"/> Induction Dose: 150 mg, followed by 450 mg IV 2 weeks later, then 450 mg IV every 24 weeks |
|                                                                    | <input type="checkbox"/> 450 mg | <input type="checkbox"/> Maintenance Dose: every 24 weeks                                                           |

Refills ☐ Zero ☐ 12 months ☐ \_\_\_\_\_ Order valid for 1 year unless otherwise stated. \_\_\_\_\_  
☒ Flush with 0.9% sodium chloride at infusion completion.  
☒ Provide nursing care per Uptiv Health Nursing Procedures, including reaction management and post-procedure observation.

**LABORATORY ORDERS**

- |                                      |                                       |                                      |
|--------------------------------------|---------------------------------------|--------------------------------------|
| <input type="checkbox"/> CBC         | <input type="checkbox"/> at each dose | <input type="checkbox"/> every _____ |
| <input type="checkbox"/> CMP         | <input type="checkbox"/> at each dose | <input type="checkbox"/> every _____ |
| <input type="checkbox"/> CRP         | <input type="checkbox"/> at each dose | <input type="checkbox"/> every _____ |
| <input type="checkbox"/> Other _____ | <input type="checkbox"/> at each dose | <input type="checkbox"/> every _____ |

**SPECIAL INSTRUCTIONS**\_\_\_\_\_  
Provider Signature\_\_\_\_\_  
Date